Quest Diagnostics Inc. (DGX) showcased an inconsistent market performance when compared to other diagnostics and research stocks. The company's stock underperformed in some instances, however strong momentum was observed which warranted closer inspection. They declared quarterly dividends, set ambitious ESG goals, launched personalized health coaching and expanded digital health offerings. They've also completed acquisitions from LifeLabs, PathAI Diagnostics and Allina Health, improving access to diagnostic innovation. Shares were purchased by Franklin Resources and Principal Financial Group, but sold by Tidal Investments. They unveiled an advanced cybersecurity framework to safeguard data and introduced specimen self-collection at their nationwide centers. They surpassed Q3 earnings and revenue estimates, upgraded their 2024 profit outlook, and their stock was given a 'Buy' rating by a few sources. They named Murali Balakumar as their Senior Vice President and CIO, advanced their green initiatives, and partnered with BD to develop companion diagnostics for cancer. Their future plans involve acquiring lab assets from OhioHealth and other entities, testing for the risk and diagnosis of Alzheimer's, and an agreement with Mainz Biomed.
Quest Diagnostics DGX News Analytics from Tue, 02 Apr 2024 07:00:00 GMT to Fri, 27 Dec 2024 22:17:00 GMT -
Rating 6
- Innovation 4
- Information 8
- Rumor -1
